Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study - Concepedia

Concepedia

Publication | Open Access

Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study

DOI Full Paper Access

87

Citations

5

References

2016

Year

Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease, Stephen Hall, Hector Chinoy, Alan Kivitz, Zailong Wang, Shephard Mpofu

The Journal of Rheumatology

Abstract

Secukinumab was efficacious in TNFi-naive and TNFi-exposed patients with PsA, with greatest improvements in TNFi-naive patients.

References

	Year	Citations

Page 1